Cure8 trial brief
New drugs in mid-stage trials may expand treatment options for people with moderate to severe Crohn's disease, especially those who have not responded to existing therapies. This trial is measuring clinical remission at 12 weeks, a common early efficacy endpoint for Crohn's studies.
Adults with moderate to severe Crohn's disease, clinicians treating IBD, and researchers interested in drug development for Crohn's disease.
This is a Phase IIa randomized, double-blind, placebo-controlled trial (NCT06450197) testing AZD7798 in adults with moderate to severe Crohn's disease.
The registry lists planned enrollment (120), primary outcome of CDAI remission at Week 12, key eligibility (18–80 years, moderate–severe CD, prior inadequate response or intolerance to conventional/advanced therapies), and many exclusion criteria including recent biologic or advanced therapy use, active infections, and prior exposure to AZD7798.
The entry describes study design and interventions (AZD7798 vs placebo) but does not report results. It is an interventional Phase 2 study that appears to assess clinical remission by CDAI at 12 weeks; other assessments (endoscopy shown in eligibility/exclusion) are part of screening and safety monitoring.
No efficacy or safety outcomes are reported in this registry record, so this listing should be treated as a trial record rather than evidence of benefit or harm.
This is a trial registry entry (Phase IIa, active_not_recruiting) and does not contain trial results. The primary outcome is CDAI remission at Week 12. AZD7798 is investigational; prior exposure to AZD7798 is an exclusion. People should not change treatment based on the registry entry and should await peer-reviewed results.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
This trial is testing whether adding vedolizumab after autologous stem cell transplant can improve remission rates for people with severe Crohn's disease that has failed multiple therapies.
This gives adults with moderately to severely active Crohn’s disease another FDA‑approved biologic option, including for people who did not respond to or could not tolerate other therapies.
Combination (dual) therapy is an active area of research because many people with Crohn’s disease don’t achieve lasting remission on a single advanced therapy. New trials suggest some combinations may improve remission...
